These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 10385550

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ, Braly P, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Najera L, Johnson D, Doroshow JH.
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [Abstract] [Full Text] [Related]

  • 5. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A, Blessing J, Bender D, Mannel R, Morgan M, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

  • 7. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

  • 8. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J.
    Acta Obstet Gynecol Scand; 2009 Feb; 88(4):463-7. PubMed ID: 19235559
    [Abstract] [Full Text] [Related]

  • 9. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M, Blessing JA, Major F, Manetta A.
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [Abstract] [Full Text] [Related]

  • 10. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C, Louvet C, Molitor JL, Dehni N, Lejeune V, Sezeur A, Pigne A, Marpeau L, Cady J, de Gramont A.
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, DeCesare S, LaPolla J, Hoffman M, Patel J.
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [Abstract] [Full Text] [Related]

  • 12. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
    Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH, Kang SB, Lee HP, Song YS.
    Ann N Y Acad Sci; 2009 Aug; 1171():627-34. PubMed ID: 19723113
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F, Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group.
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [Abstract] [Full Text] [Related]

  • 17. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 18. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
    Homesley HD, Bundy BN, Hurteau JA, Roth LM.
    Gynecol Oncol; 1999 Feb 01; 72(2):131-7. PubMed ID: 10021290
    [Abstract] [Full Text] [Related]

  • 19. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, Conte PF.
    Gynecol Oncol; 2000 Feb 01; 76(2):157-62. PubMed ID: 10637064
    [Abstract] [Full Text] [Related]

  • 20. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
    Hochster HS, Plimack ER, Mandeli J, Wadler S, Runowicz C, Goldberg G, Speyer J, Wallach R, Muggia F, New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology.
    Gynecol Oncol; 2006 Feb 01; 100(2):324-9. PubMed ID: 16253316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.